Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moxifloxacin + penicillin G is a combination of two antibiotics used for the treatment of bacterial infections. Moxifloxacin is a fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. Penicillin G (benzylpenicillin) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. This combination may be considered in severe or mixed infections where broad-spectrum coverage against both gram-positive and gram-negative bacteria is desired or when synergistic effects are sought to enhance bactericidal activity or prevent resistance emergence[2][4]. Both agents are administered parenterally in clinical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moxifloxacin + penicillin G.